ClinicalTrials.Veeva

Menu

Atorvastatin/CoenzymeQ10 in Congestive Heart Failure

I

Isfahan University of Medical Sciences

Status

Unknown

Conditions

Congestive Heart Failure

Treatments

Drug: placebo for coenzyme Q10
Drug: Coenzyme Q10
Drug: Atorvastatin

Study type

Interventional

Funder types

Other

Identifiers

Details and patient eligibility

About

The aim of this study is to compare the effect of addition of combination of Atorvastatin/CoenzymeQ10 to standard congestive heart failure (CHF) treatment versus addition of Atorvastatin alone on CHF outcomes.

Enrollment

30 estimated patients

Sex

All

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Documented Congestive hear failure
  • Ejection Fraction less than 40 percent
  • Compensated heart failure without hospital admission during previous three months
  • No change in type and dose of medications in the last months
  • New York Heart Association Function Class 2 to 4

Exclusion criteria

  • Acute coronary syndrome developing in the last month
  • Active myocarditis
  • Active pericarditis
  • Uncontrolled hypertension
  • Hepatic failure(Child B,C)
  • Pulmonary failure
  • Renal failure
  • Heart failure with KILLIP classification 3 and 4

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Double Blind

30 participants in 2 patient groups

Coenzyme Q10 & Atorvastatin
Experimental group
Description:
10 mg Atorvastatin daily plus 100 mg Coenzyme Q10 pearl supplement twice daily for four months.
Treatment:
Drug: Coenzyme Q10
Drug: Atorvastatin
Atorvastatin & placebo
Active Comparator group
Description:
10 mg Atorvastatin daily and the placebo of Coenzyme Q10 pearl for four months.
Treatment:
Drug: placebo for coenzyme Q10
Drug: Atorvastatin

Trial contacts and locations

1

Loading...

Central trial contact

Amin Nemati, MD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems